Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
International Journal of Cardiology|December 4, 2014
Temporal trends in management and outcome of diabetic and non-diabetic patients with acute coronary syndrome (ACS): residual risk of long-term mortality persists: Insights from the ACS Israeli Survey (ACSIS) 2000-2010Robert Klempfner, Avishay Elis, Shlomi Matezky, et al.
Clinical Nutrition (Edinburgh, Scotland)|December 3, 2015
Improved meal presentation increases food intake and decreases readmission rate in hospitalized patientsDaniela Abigail Navarro, Mona Boaz, Ilan Krause, et al.
Stress (Amsterdam, Netherlands)|February 4, 2025
Assessment of depression in patients admitted with acute coronary syndrome: a double-blind studyEla Giladi, Sapir Tzadok, Tamar Shitrit, et al.
Coronary Artery Disease|August 21, 2025
Temporal trends in the treatment with beta-blocker and the effect on outcome of patients with acute myocardial infarctionEla Giladi, Ilya Losin, Ziad Arow, et al.
American Heart Journal|December 3, 2014
Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: rationale and design of a randomized controlled trialEdward Koifman, Ehud Grossman, Avishay Elis, et al.
Leukemia & Lymphoma|May 13, 2006
Fertility status among women treated for aggressive non-Hodgkin's lymphomaAvishay Elis, Aharon Tevet, Ronit Yerushalmi, et al.
Biomedicines|February 27, 2026
Sex-Based Differences in SGLT2i and GLP-1RA Use and Mortality in T2DM with Atherosclerotic Cardiovascular DiseaseHana Vaknin-Assa, Ammie Wolf, Ranin Hilu, et al.
Cardiology|January 24, 2021
Thrombin Generation in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary InterventionChen Gurevitz, Alon Eisen, Eli Lev, et al.
Harefuah|January 21, 2021
[UPDATED ISRAELI GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA 2020]Hofit Cohen, Ronen Durst, Ophir Avizohar, et al.
The Lancet. Diabetes & Endocrinology|January 27, 2025
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trialFrederick J Raal, Vimal Mehta, Meral Kayikcioglu, et al.
Pageof 10